Market evolution: Plastic syringes (CN 90183110) — 2015–2025

Introduction

This report analyses the evolution of the European Union's external trade in plastic syringes (CN 90183110) between 2015 and 2025. Over this period, the EU market for these essential medical devices has undergone significant structural shifts. While both exports and imports have grown substantially in value, the dynamics of this growth have been markedly different, leading to a fundamental change in the EU's trade balance. The following sections explore the primary drivers of this transformation, including divergent growth patterns in trade value, a restructuring of EU production and specialisation, and the implications of increased external dependency coupled with supply chain volatility.

1. From trade surplus to deficit: value-driven growth outpaces volume

The decade between 2015 and 2025 was characterised by robust growth in both the value and quantity of EU trade in plastic syringes. However, the growth in trade value dramatically outstripped the increase in physical quantities, indicating a significant rise in average unit prices and a shift towards higher-value products or market conditions.

1.1. Divergent growth trajectories between exports and imports

The EU's exports and imports both expanded significantly, but imports grew at a much faster rate. Export value increased by 96.9%, rising from €413.3 million in 2015 to €814.0 million in 2025. In contrast, import value surged by 190.1%, from €382.0 million to €1,107.9 million over the same period. This disparity directly led to the erosion and reversal of the EU's trade position.

The EU moved from a modest trade surplus of €31.4 million in 2015 to a substantial deficit of €293.9 million in 2025. This swing represents a change of over €325 million.

1.2. The primacy of price over volume in trade value expansion

The increase in trade value was largely fuelled by rising prices rather than by proportional increases in traded volumes. EU export quantities grew by only 10.2%, while their value nearly doubled. This resulted in a 78.8% increase in the average export price (EUR per tonne). Similarly, while import volumes grew by 73.7%, their value nearly tripled, leading to a 67.0% increase in the average import price. This inflationary trend points towards a market-wide increase in the value of medical plastic syringes, potentially driven by technological upgrades, material costs, or a shift in the product mix towards more sophisticated items.

1.3. Key bilateral relationships and the central role of China

The top trade partners highlight the globalised nature of this market and the pivotal role of China. China was the top source of EU imports by value in 2025, with its imports growing by 247% since 2015. Simultaneously, China also represented the third-largest destination for EU exports, with exports growing by 123%. The United States was a major partner on both sides: the largest export destination and the second-largest import source. Notably, Switzerland showed extreme growth on both fronts, becoming a key import source (up 291%) and a major export destination (up 341%).

2. Internal production transformation and diverging member state specialisation

Behind the aggregate trade figures lies a story of significant restructuring within the EU's domestic production and a diverging export specialisation among its member states.

2.1. A shift in EU production: higher value from fewer units

EU production data reveals a stark transformation. The number of items produced plummeted by 39.6%, from over 12.4 billion units in 2015 to 7.5 billion in 2025. Conversely, the value of this production surged by 160.9%, from €690 million to €1.8 billion. This indicates a fundamental strategic shift: EU manufacturers are producing far fewer individual syringes but generating much more revenue from them. This strongly suggests a move up the value chain towards premium, specialised, or higher-margin syringe products, possibly exiting from bulk, low-value segments.

2.2. The geography of specialisation within the EU

Export specialisation varies widely across the EU. Denmark and Czechia lead as the most specialised exporters of plastic syringes, with high Revealed Symmetric Comparative Advantage (RSCA) indices. Germany, while having a moderate specialisation score (RSCA: 0.15), is the undisputed volume leader, accounting for 28.6% of EU production value and 21.2% of total exports in 2025. France and the Netherlands have also emerged as major exporters, with French export value growing by an impressive 409% over the period. In contrast, several member states like Greece, Malta, and Lithuania show no specialisation in this product category.

3. Deepening external dependency and susceptibility to price shocks

The structural shifts in trade and production have directly impacted the EU's supply chain resilience, increasing its net dependency on imports and exposing it to significant price volatility from key partners.

3.1. From self-sufficiency to net import reliance

The EU's net import reliance has transformed dramatically. In 2015, the EU was a net exporter (reliance: -4.8%). By 2025, it had become a significant net importer, with a reliance ratio of 23.3%. This metric confirms the findings from the trade balance and underscores the EU's increased dependency on non-EU suppliers to meet domestic demand. The shift aligns with the strategic reduction in the volume of domestic production.

3.2. Price volatility and detected supply shocks

Trade with several partners has been characterised by high price volatility. Imports from Taiwan and the Philippines, for instance, showed very high coefficient of variation (CV) values of 0.79 and 0.70 respectively. The volatility analysis also detected notable price shock events. The most significant was a 149.4% price shock in imports from China centred in 2021, likely reflecting pandemic-related demand surges and supply chain disruptions. Another major price shock was detected in EU exports to Canada in 2022. These events highlight the market's sensitivity to geopolitical and logistical disturbances.

3.3. Concentration of trade flows

The Herfindahl-Hirschman Index (HHI) indicates that import sources are more concentrated than export destinations. The import HHI (by value) stood at 2212 in 2025, while the export HHI was 886. Although import concentration decreased slightly over the decade, it remains at a level indicating a moderately concentrated market structure, which, combined with the high volatility from certain partners, poses a risk to supply security.

Conclusion

Between 2015 and 2025, the EU's market for plastic syringes underwent a profound transformation. The most definitive change was the shift from a net exporter to a substantial net importer, driven by import value growth outstripping exports. This was not a story of declining exports, which grew healthily, but of even more explosive import growth. Concurrently, EU production strategy pivoted decisively towards fewer, higher-value items. The resulting increased external dependency, coupled with significant price volatility from key partners like China, underscores a new vulnerability in the supply chain for these critical medical devices. The market has evolved into one where the EU is a major, specialised exporter of high-value products but is simultaneously dependent on global imports to meet overall demand, a configuration that requires careful management of trade relationships and supply risks.